TP53 mutation had an adverse impact on OS and EFS in AML‐MRC‐C (HR 2.52, 95% CI 1.62–3.93, p < 0.0001 and HR 2.14, 95% CI 1.42–3.21, p = 0.0002, respectively). This evidence concerns the gene TP53 and acute myeloid leukemia.